Cytosorbents (CTSO) Capital Expenditures (2011 - 2026)

Cytosorbents (CTSO) has reported Capital Expenditures for 16 consecutive years, with $14000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures rose 106.54% year-over-year to $14000.0; the trailing twelve-month figure through Jun 2026 stood at $150000.0 (down 42.31% YoY), and the FY2025 full-year result was $164000.0, down 42.25% from the prior year.
• Capital Expenditures improved to $14000.0 in Q2 2026 per CTSO's latest filing, from $11000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $3.1 million in Q2 2022 and bottomed at -$214000.0 in Q2 2025.
• Historically, Capital Expenditures has averaged $394360.0 across 5 years, with a median of $101748.5 in 2023.
• The widest YoY moves for Capital Expenditures: up 459.85% in 2025, down 1301.64% in 2025.
• Over 5 years, Capital Expenditures stood at $213437.0 in 2022, then tumbled by 55.26% to $95497.0 in 2023, then slipped by 27.75% to $69000.0 in 2024, then jumped by 56.52% to $108000.0 in 2025, then tumbled by 87.04% to $14000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $14000.0, $11000.0, and $108000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.